Overview
RCKT market data
Price History
RCKT price chart · 1M
- O
- 3.70
- H
- 3.70
- L
- 3.58
- C
- 3.67
- Vol
- 54,616.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $3.70
- Previous Close
- $3.78
- Day High
- $3.70
- Day Low
- $3.58
- 52 Week High
- $5.45
- 52 Week Low
- $2.53
- 7 Day Return
- +0.41%
- 30 Day Return
- +13.27%
- 90 Day Return
- +21.93%
- 1 Year Return
- -16.78%
- Daily Notional Volume
- $200.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.01 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.46 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.53 – $5.45 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $368.3M · P/B 1.37.
Company News
Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15Benzinga · Aug 11, 2026, 1:52 PM
Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 EstimateBenzinga · Aug 10, 2026, 8:21 PM
Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy TrialBenzinga · Aug 3, 2026, 4:03 PM
Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon DiseaseBenzinga · Aug 3, 2026, 11:14 AM
Rocket Pharmaceuticals Closes Sale Of Its Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $180MBenzinga · Jun 12, 2026, 11:05 AM